A retrospective study of californium-252 neutron brachytherapy combined with EBRT versus 3D-CRT in the treatment of esophageal squamous cell cancer

Radiation Oncology

C-K Chris Wang³  Bo Liu²  Xitang Jia²  Huiming Liu²  Jian Wang¹  Jie Wang¹  Jinyi Lang¹  Tao Li¹  Qifeng Wang¹ 

[1] Department of Radiation Oncology, Sichuan Cancer Hospital, Chengdu 610041, Sichuan, P.R. China;Department of Radiation Oncology, Changzhi Cancer Hospital, Changzhi 046000, Shanxi, P.R. China;Medical Physics Program, School of Mechanical Engineering, Georgia Institute of Technology, Atlanta 30332-0745, GA, USA

关键词: Relative biological effectiveness (RBE);    High-LET;    Neutron brachytherapy (NBT);    Esophageal squamous cell carcinoma (ESCC);   

Others  :  1232607
DOI  :  10.1186/s13014-015-0520-7

 received in 2015-05-29, accepted in 2015-10-13,  发布年份 2015

【 摘 要 】

Background

We conducted a retrospective analysis on 884 patients who were diagnosed with esophageal squamous cell carcinoma (ESCC) and treated with either the neutron brachytherapy in combination with external beam radiotherapy (NBT + EBRT) or 3-dimensional conformal radiation therapy (3D-CRT) to determine the differences in efficacy and morbidity between the two treatment groups.

Methods

The 884 ESCC patients treated with either NBT + EBRT or 3D-CRT between 2002 and 2012 were retrospectively reviewed and analyzed. Multivariable Cox regression was used to compare oncologic outcomes of the two groups of patients in the context of other clinically relevant variables. The acute and chronic toxicities associated with the two groups were compared using Fisher exact and log-rank tests, respectively.

Results

Among the 884 patients, 545 received NBT + EBRT and 339 received 3D-CRT (i.e. EBRT-only). The age range is 39–95 years (median 66). The follow-up time range is 3–145 months (median 32). The analysis shows that the NBT + EBRT group has higher overall survival rate and local control rate than that of the 3D-CRT group. The acute toxicity effects were acceptable for both groups of patients with the NBT + EBRT group showing higher rates of leukopenia and thrombocytopenia and the 3D-CRT group showing higher rates on fistula and massive bleeding.

Conclusions

The patients treated with NBT + EBRT showed better oncologic outcomes than those treated with 3D-CRT. The toxicity effects were acceptable for both groups with the NBT + EBRT group showing higher rates on the acute effects and the 3D-CRT group showing higher rates on the late effects.

【 授权许可】

   
2015 Wang et al.

【 图 表 】

Fig. 1.

Fig. 2.

【 参考文献 】

• [1]Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010; 19(8):1893-1907.
• [2]Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg D et al.. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008; 26(7):1086-92.
• [3]Liao Z, Komaki RR, Thames HD, Liu HH, Tucker SL, Mohan R et al.. Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2010; 76(3):775-81.
• [4]Liu H, Wang Q, Wan X, Jia X, Liu B, Wang CC. Californium-252 neutron brachytherapy combined with external beam radiotherapy for esophageal cancer: Long-term treatment results. Brachytherapy. 2014; 13:514-21.
• [5]Welsh J, Settle SH, Amini A, Xiao L, Suzuki A, Hayashi Y et al.. Failure patterns in patients with esophageal cancer treated with definitive chemoradiation. Cancer. 2012; 118(10):2632-40.
• [6]Common terminology criteria for adverse events (CTCAE), v3.0. U.S. Department of Health and Human Services; Washington DC. 2006. http://ctep. cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf webcite
• [7]Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R et al.. INT 0123 (Radiation Therapy Oncology Group 94–05) phase III trial of combined-modality therapy for esophageal cancer: highdose versus standard-dose radiation therapy. J Clin Oncol. 2002; 20(5):1167-74.
• [8]Myles BA, Lin SH, Tucker SL, Ajani JA, Hofstetter WL, Swisher SG et al.. Long term outcomes comparing three-dimensional conformal radiation therapy to intensity modulated radiation therapy with concurrent chemotherapy for the treatment of esophageal cancer: The MD Anderson experience. Int J Radiat Oncol Biol Phys. 2011; 81(2):S127.
• [9]Xiao Z, Zhang Z, Zhang H, Dai J, Liang J, Han W. Assessment of tumor dose distribution in three dimensional conformal radiotherapy treatment planning system for esophageal cancer. Chin J Radiat Oncol. 2004; 13(4):273-277.
• [10]Niu D, Hu H, Ren C, Qu Z. Three dimensional conformal radiation therapy for esophageal carcinoma. Chin J Radiat Oncol. 2004; 13(3):193-195.
• [11]Li R, Zhu S, Shen W, Qiu R, Wang Y, Li J. Effects of different radiotherapy techniques on 170 cases with esophageal carcinoma. Chin J Clin Oncol. 2007; 34(19):1112-1115.
• [12]Samerdokiene V, Valuckas KP, Janulionis E, Atkocius V, and Rivard MJ. Second primary malignancies after radiotherapy including HDR 252Cf brachytherapy for cervical cancer. Brachytherapy 2015. doi:10.1016/j.brachy.2015.06.006.